The Relationship Between Proton Pump Inhibitor Adherence and Fracture Risk in the Elderly

被引:0
作者
Jian Ding
Debra A. Heller
Frank M. Ahern
Theresa V. Brown
机构
[1] Magellan Health Services/PACE,Department of Biobehavioral Health
[2] The Pennsylvania State University,undefined
[3] Pennsylvania Department of Aging,undefined
来源
Calcified Tissue International | 2014年 / 94卷
关键词
Proton pump inhibitor; Medication adherence; Fracture; Elderly;
D O I
暂无
中图分类号
学科分类号
摘要
Studies suggest that long-term use of proton pump inhibitors (PPIs) may be associated with an increased risk of fracture. However, the role of medication adherence in this association is not fully understood. A retrospective cohort study was conducted to examine the relationship between PPI use/adherence and fracture risk among elderly subjects by combining administrative pharmacy claims data, survey data, and Medicare data. The study cohort included 1,604 PPI users and 23,672 nonusers who were enrolled in Pennsylvania’s Pharmaceutical Assistance Contract for the Elderly program. PPI adherence was measured by the proportion of days covered (PDC). Time-dependent Cox proportional hazards models were used to estimate adjusted hazard ratios (HRs) of PPI use/adherence for fracture risk while controlling for demographics, comorbidity, body mass index, smoking, and non-PPI medication use. The overall incidence of any fracture per 100 person-years was 8.7 for PPI users and 5.0 for nonusers. A gradient in fracture risk according to PPI adherence was observed. Relative to nonusers, fracture HRs associated with the highest (PDC ≥ 0.80), intermediate (PDC 0.40–0.79), and lowest (PDC <0.40) adherence levels were 1.46 (p < 0.0001), 1.30 (p = 0.02), and 0.95 (p = 0.75), respectively. In addition, the fracture risk of PPI use was significant for hip (HR = 1.32, p = 0.04) and vertebral (HR = 1.69, p = 0.0005) fractures, and risk was similar between major osteoporotic and other fractures. These results provide further evidence that PPI use may increase fracture risk in the elderly and highlight the need for clinicians to periodically reassess elderly patients’ individualized needs for ongoing PPI therapy, while weighing potential risks and benefits.
引用
收藏
页码:597 / 607
页数:10
相关论文
共 191 条
  • [1] Woolf AD(2003)Preventing fractures in elderly people BMJ 327 89-95
  • [2] Akesson K(2012)Osteoporotic fractures: a systematic review of US healthcare costs and resource utilization Pharmacoeconomics 30 147-170
  • [3] Budhia S(2002)Epidemiology and outcomes of osteoporotic fractures Lancet 359 1761-1767
  • [4] Mikyas Y(2009)Assessment of fracture risk Eur J Radiol 71 392-397
  • [5] Tang M(1998)Epidemiology of medication-related falls and fractures in the elderly Drugs Aging 12 43-53
  • [6] Badamgarav E(2009)Meta-analysis of the impact of 9 medication classes on falls in elderly persons Arch Intern Med 169 1952-1960
  • [7] Cummings SR(2006)Long-term proton pump inhibitor therapy and risk of hip fracture JAMA 296 2947-2953
  • [8] Melton LJ(2006)Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture Calcif Tissue Int 79 76-83
  • [9] Kanis JA(2008)Use of proton pump inhibitors and risk of osteoporosis-related fractures CMAJ 179 319-326
  • [10] Johansson H(2008)Acid-suppressive medications and risk of bone loss and fracture in older adults Calcif Tissue Int 83 251-259